ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
Stromal graft rejection after deep anterior lamellar keratoplasty at a tertiary care center.
Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the characteristics and outcomes of stromal rejection after deep anterior lamellar keratoplasty (DALK) at a tertiary care center in Saudi Arabia.
methodsThe clinical records of 42 patients who underwent DALK between January 2019 and December 2023 were reviewed to identify patients who had experienced stromal rejection. Those patients were analyzed in terms of biodata, indications for surgery, graft size, subjective and objective clinical findings, treatment courses, and follow-ups.
resultsOf the 42 cases of DALK conducted during the study in our center, 3 (7.1%) experienced graft rejection between postoperative months 8 and 18. The mean age of patients with rejection at presentation was 30.6 years, compared to 33.5 years for those without rejection. The mean follow-up durations were 16.6 months for patients with rejection and 25.7 months for patients without rejection. All patients started intensive topical prednisolone acetate 1% (half hourly to hourly) on first presentation, and one had a pulse of intravenous methylprednisolone. A complete recovery was observed in all patients after 1-2 weeks.
conclusionWhile DALK offers significant advantages over full-thickness corneal grafting, graft rejection remains a potential complication. Early presentation and timely treatment of rejection after DALK carry a good prognosis and can prevent graft failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.